drugset / Trial / NCT02175602

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

NCT02175602

Phase 1 Completed 41 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the effect of Daclatasvir, Asunaprevir, and BMS-791325 on the pharmacokinetics of selective serotonin reuptake inhibitors.

Timeline

Start
2014-06
Primary completion
2014-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Asunaprevir Small molecule 200 mg Oral
Subject Beclabuvir Small molecule 75 mg Oral
Subject Daclatasvir Small molecule 30 mg Oral
Subject Escitalopram Small molecule 10 mg
Subject Sertraline Small molecule 50 mg